Sen. Hatch, Biopharma Industry Champion, Ready To Hang Up His Gloves
Hatch had a hand in major bipartisan legislation creating markets for generic drugs, orphan drugs, biosimilars, and dietary supplements.
You may also be interested in...
'Big Shoes To Fill' As Hatch Retirement Leaves Supplement Market Legacy
Sen. Orrin Hatch won’t seek re-election and will leave 24 years after Congress passed the Dietary Supplement Health and Education Act as a framework for FDA's regulation of vitamin, mineral and supplement product manufacturing and marketing. Hatch is in his seventh term and is the longest-serving Senate member.
Medicare Price Negotiations: HHS Nominee Suggests Adapting Part D 'Learnings' To Part B
Alex Azar talks about price negotiation in Medicare Part B, whether his biopharma industry ties would influence his decisions as head of HHS, insulin price increases and importation during the first of his confirmation hearings.
Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents
Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.